Tenofovir Disoproxil Emtricitabine shortage status
Partial shortage
Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Tenofovir Disoproxil Emtricitabine products are in shortage in Canada (2 of 5 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer.
A combination antiviral used to treat and prevent HIV infection.
Products affected
2 / 5
In shortage since
Jan 20, 2025
Reports on file
24
Talk to a pharmacist
Pharmacists can substitute an unaffected manufacturer's version, adjust strengths, and in most provinces adapt or renew a prescription on the spot.
Independent services, not affiliated with rxstat; referral fees may apply. Free options exist depending on your province. In an emergency call 911; free health advice at 811.
Shortage history
Shortage history (red bands = periods in shortage).
Reports by product
The DIN is printed on your prescription label.
Active shortage
TEVA-EMTRICITABINE/TENOFOVIR
300MG
200MG · TABLET · TEVA CANADA LIMITED
DIN 02399059 · since Jan 20, 2025, no end estimate · Disruption of the manufacture of the drug.
Active shortage
MYLAN-EMTRICITABINE/TENOFOVIR DISOPROXIL
200MG
300MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02443902 · since May 16, 2025, no end estimate · Disruption of the manufacture of the drug.
Resolved
PMS-EMTRICITABINE-TENOFOVIR
300MG
200MG · TABLET · PHARMASCIENCE INC
DIN 02461110 · ended Jun 18, 2025 · Disruption of the manufacture of the drug.
Resolved
APO-EMTRICITABINE-TENOFOVIR
200MG
300MG · TABLET · APOTEX INC
DIN 02452006 · ended May 1, 2025 · Disruption of the manufacture of the drug.
Resolved
AURO-EMTRICITABINE-TENOFOVIR
200MG
300MG · TABLET · AURO PHARMA INC
DIN 02490684 · ended Apr 22, 2025 · Demand increase for the drug.
Resolved
MYLAN-EMTRICITABINE/TENOFOVIR DISOPROXIL
200MG
300MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02443902 · ended Mar 31, 2025 · Disruption of the manufacture of the drug.
Resolved
AURO-EMTRICITABINE-TENOFOVIR
200MG
300MG · TABLET · AURO PHARMA INC
DIN 02490684 · ended Jul 29, 2024 · Demand increase for the drug.
Resolved
TEVA-EMTRICITABINE/TENOFOVIR
300MG
200MG · TABLET · TEVA CANADA LIMITED
DIN 02399059 · ended Jun 20, 2023 · Disruption of the manufacture of the drug.
Resolved
APO-EMTRICITABINE-TENOFOVIR
200MG
300MG · TABLET · APOTEX INC
DIN 02452006 · ended May 16, 2023 · Disruption of the manufacture of the drug.
Resolved
MYLAN-EMTRICITABINE/TENOFOVIR DISOPROXIL
200MG
300MG · TABLET · MYLAN PHARMACEUTICALS ULC
DIN 02443902 · ended Feb 3, 2022 · Shortage of an active ingredient.
Resolved
APO-EMTRICITABINE-TENOFOVIR
300MG
200MG · TABLET · APOTEX INC
DIN 02452006 · ended Jun 4, 2021 · Disruption of the manufacture of the drug.
Resolved
TEVA-EMTRICITABINE/TENOFOVIR
200MG
300MG · TABLET · TEVA CANADA LIMITED
DIN 02399059 · ended Jan 6, 2021 · Disruption of the manufacture of the drug.
Showing 12 of 24 reports. All reports are on file with Health Canada.
What's happening
Tenofovir Disoproxil Emtricitabine is currently affected by 2 active shortage reports filed with Health Canada by TEVA CANADA LIMITED, MYLAN PHARMACEUTICALS ULC.
The reported cause is: disruption of the manufacture of the drug. Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Tenofovir Disoproxil Emtricitabine is classified under “DIRECT ACTING ANTIVIRALS” (ATC J05AR).
Recent changes
No changes recorded yet.
Common questions
What is Tenofovir Disoproxil Emtricitabine used for?
A combination antiviral used to treat and prevent HIV infection.
When will Tenofovir Disoproxil Emtricitabine be back in stock in Canada?
Manufacturers have not provided a reliable end date. This page updates automatically as soon as an estimate is filed.
Why is Tenofovir Disoproxil Emtricitabine in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
Email alerts
Get an email when this drug's status changes. Double opt-in, one-click unsubscribe.
Drugs in the same therapeutic class, best-supplied first. These are not automatic substitutes: only your pharmacist or prescriber can judge whether a switch makes sense for you.
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.